Was sich geändert hat
Was sich geändert hatZwischen dem 14. September und dem 29. September 2026 führte Eli Lilly mehrere klinische Studien durch, darunter Untersuchungen neuer Verbindungen sowie den Abschluss einer Phase-4-Studie zur Diabetes-Behandlung. Diese Aktivitäten zielen darauf ab, das therapeutische Potenzial experimenteller Wirkstoffe und neue Indikationen für bestehende Medikamente zu bewerten.

Unternehmensverlauf
Oktober 2026
ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-10.
- 2026-10-08: Participants receive eloralintide subcutaneously as the experimental intervention. Quelle
- 2026-10-08: Participants receive single doses of LY4268989 in six treatment arms, with high‑fat and fasted states. Quelle
- 2026-10-08: The study enrolls 123 healthy participants and includes four inpatient stays at the clinical research unit. Quelle
- 2026-10-08: The study has four parts: single-ascending dose, multiple-ascending dose, single dose in three periods, and midazolam co‑administration. Quelle
- 2026-10-08: The trial is recruiting participants with overweight or prediabetic conditions to receive the investigational drug Orforglipron orally. Quelle
- 2026-10-08: Participants will receive LY4329090 administered subcutaneously (SC). Quelle
- 2026-10-08: The study includes two parts: Part A lasting about 10 weeks with 5 nights stay and 5 outpatient visits, Part B lasting about 21 weeks with 4 stays totaling 11 nights and 14 outpatient visits. Quelle
- 2026-10-08: The study is a randomized, parallel, double‑masked, basic science interventional study with estimated enrollment of 184 participants. Quelle
- 2026-10-08: The study will enroll 161 participants and is a Phase 2 randomized, open-label, parallel-design intervention study. Quelle
- 2026-10-08: The study will evaluate vepugratinib in adults with low‑grade, intermediate‑risk non‑muscle invasive bladder cancer or low‑grade upper tract urothelial carcinoma. Quelle
- 2026-10-09: The primary purpose of the study is basic science evaluating the safety and tolerability of LY5625575. Quelle
- 2026-10-09: The study will include healthy participants and participants with elevated high-sensitivity C-reactive protein. Quelle
September 2026
ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-09.
- 2026-09-23: The intervention includes abemaciclib in three formulations: Tablet Test Formulation 1, Oral Granules Test Formulation 2, and Reference Tablet Formulation 1. Quelle
- 2026-09-23: The trial will last about 8 weeks, including screening and follow-up. Quelle
- 2026-09-24: The trial is a phase 2, nonrandomized, sequential, open-label, single‑arm study of mosunetuzumab plus pirtobrutinib in relapsed or refractory Waldenstrom’s Macroglobulinemia. Quelle
- 2026-09-24: Patients must be ≥18 years with measurable Waldenstrom’s Macroglobulinemia and have relapsed or refractory disease after at least one prior line of therapy. Quelle
- 2026-09-24: The total number of cycles administered is 18 for patients with a complete, very good partial or minor response in dosing strategy 1 and 19 in dosing strategy 2. Quelle
- 2026-09-28: The trial is a prospective, single-arm, nonrandomized, open-label, phase I/II study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) in patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases. Quelle
- 2026-09-28: Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. Quelle
- 2026-09-28: The trial intervention included subcutaneous injections of insulin lispro-aabc (also known as LY900014 or Lyumjev) combined with insulin glargine (Basaglar). Quelle
- 2026-09-28: The company's product, baricitinib (Olumiant), was evaluated in a Phase 2 study for the treatment of central centrifugal cicatricial alopecia in adults of African descent. Quelle
- 2026-09-28: In a Phase 2 trial of baricitinib for central centrifugal cicatricial alopecia, 27 participants received at least one dose and 17 completed the 52-week treatment period. Quelle
- 2026-09-29: Eli Lilly and Company is conducting a Phase 1 study to evaluate the tolerability and side effects of the drug LY4057996 in healthy participants and those with Type 1 or Type 2 Diabetes. Quelle
- 2026-09-29: The study arms include experimental groups testing LY4057996 administered subcutaneously or intravenously, alone or in combination with other agents such as Lispro and basal insulin, against placebo and active comparators. Quelle
Monatliche Einträge werden von der KI aus den geprüften Berichten und offiziellen Quellen des jeweiligen Monats erstellt (auf Englisch, wie entnommen), jede Zeile verlinkt ihre Quelle; Handlungsstränge bündeln zusammengehörige Entwicklungen über Analysen hinweg mithilfe von Vektor-Embeddings (Amazon Titan Text Embeddings V2). Vorläufiger Kontext, keine Anlageberatung.
Sektorvergleich
Vergleich mit 36 beobachteten Unternehmen im Sektor Gesundheit (Median Umsatzveränderung +7,2% J/J) aus archivierten SEC-XBRL-Daten.
| Unternehmen | Letzter Umsatz | Umsatz J/J | Operative Marge |
|---|
| ELI Lilly & Co LLY | 24,4 Mrd. $ | +38,6% | — |
| Unitedhealth Group Inc UNH | 113 Mrd. $ | -0,4% | 5,8% |
| Mckesson Corp MCK | 111 Mrd. $ | +7,6% | 1,4% |
| CVS Health Corp CVS | 108 Mrd. $ | +5,4% | 3,3% |
| Cigna Group CI | 73,7 Mrd. $ | +5,6% | 3,3% |
| Cardinal Health Inc CAH | 67,5 Mrd. $ | +5,5% | 1,1% |
| Elevance Health, Inc. ELV | 51,4 Mrd. $ | +1,4% | 2,5% |
Jeweils jüngster Berichtszeitraum laut SEC CompanyFacts (XBRL). Geschäftsjahre können abweichen.
Große Fonds (13F)
| Fonds | Aktien | Wert | Veränderung der Aktien | Quartal |
|---|
| BlackRock | 67.936.153 | $78.607.563.355 | +0,6% | Q3 2026 |
| State Street | 36.848.565 | $42.636.737.590 | +1,7% | Q3 2026 |
| Fidelity (FMR) | 29.959.147 | $34.665.130.320 | +5,3% | Q3 2026 |
| Geode Capital Management | 20.556.572 | $23.722.722.425 | +1,2% | Q3 2026 |
| Capital Research Global Investors | 16.998.595 | $19.670.092.948 | -18,6% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 11.471.413 | $13.759.156.895 | — | Q2 2026 |
| Wellington Management | 11.048.493 | $12.783.990.282 | +0,5% | Q3 2026 |
| Citadel Advisors | 681.483 | $788.530.350 | -27,9% | Q3 2026 |
| Two Sigma Investments | 339.220 | $392.504.678 | +317,6% | Q3 2026 |
| D. E. Shaw & Co. | 316.379 | $366.075.814 | -36,3% | Q3 2026 |
| Millennium Management | 199.938 | $231.344.261 | +9,4% | Q3 2026 |
| ARK Investment Management (Cathie Wood) | 107.838 | $124.776.742 | +39,6% | Q3 2026 |
| Bridgewater Associates | 94.722 | $109.600.932 | +8,8% | Q3 2026 |
| Soros Fund Management | 22.199 | $25.686.019 | 0,0% | Q3 2026 |
| T. Rowe Price | 13.383.370 | $15.485.631 | -3,8% | Q3 2026 |
Aus den vierteljährlichen 13F-HR-Berichten der großen Fonds, die wir verfolgen, wie gemeldet. Fonds melden bis zu 45 Tage nach Quartalsende, die Positionen können sich seitdem geändert haben. Veränderung: gegenüber dem Vorquartal desselben Fonds. Keine Empfehlung.